Details
Stereochemistry | ACHIRAL |
Molecular Formula | C4H11NO3 |
Molecular Weight | 121.135 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
NC(CO)(CO)CO
InChI
InChIKey=LENZDBCJOHFCAS-UHFFFAOYSA-N
InChI=1S/C4H11NO3/c5-4(1-6,2-7)3-8/h6-8H,1-3,5H2
Molecular Formula | C4H11NO3 |
Molecular Weight | 121.135 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionCurator's Comment: Description was created based on several sources, including
https://www.drugs.com/pro/tham.html
https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=NCI_Thesaurus&code=C47775
http://www.cir-safety.org/sites/default/files/Tromet_092013_Rep.pdf
Curator's Comment: Description was created based on several sources, including
https://www.drugs.com/pro/tham.html
https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=NCI_Thesaurus&code=C47775
http://www.cir-safety.org/sites/default/files/Tromet_092013_Rep.pdf
Tromethamine is extensively used in biochemistry and molecular biology. Because tromethamine (in the form of R-NH2) is a proton acceptor with a pK of 7.8, it is an effective buffer that can
be used to maintain the pH of body fluids. Tromethamine is indicated for the prevention and correction of metabolic acidosis. When administered intravenously as a 0.3 M solution, tromethamine acts as a proton acceptor and prevents or corrects acidosis by actively binding hydrogen ions (H+). It binds not only cations of fixed or metabolic acids, but also hydrogen ions of carbonic acid, thus increasing bicarbonate anion (HCO3‾). TromeThamine also acts as an osmotic diuretic, increasing urine flow, urinary pH, and excretion of fixed acids, carbon dioxide and electrolytes. A significant fraction of tromethamine (30% at pH 7.40) is not ionized and therefore is capable of reaching equilibrium in total body water. This portion may penetrate cells and may neutralize acidic ions of the intracellular fluid.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: GO:0006816 Sources: https://www.ncbi.nlm.nih.gov/pubmed/6476981 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Tham Approved Useindicated for the prevention and correction of metabolic acidosis. In the following conditions it may help to sustain vital functions and thus provide time for treatment of the primary disease:
Metabolic Acidosis Associated with Cardiac Bypass Surgery.
Tham Solution has been found to be primarily beneficial in correcting metabolic acidosis which may occur during or immediately following cardiac bypass surgical procedures.
Correction of Acidity of ACD Blood in Cardiac Bypass Surgery.
It is well known that ACD blood is acidic and becomes more acidic on storage. TromeThamine effectively corrects this acidity. Tham Solution may be added directly to the blood used to prime the pump-oxygenator. When ACD blood is brought to a normal pH range the patient is spared an initial acid load. Additional tromeThamine may be indicated during cardiac bypass surgery should metabolic acidosis appear.
Metabolic Acidosis Associated with Cardiac Arrest. Launch Date1965 |
PubMed
Title | Date | PubMed |
---|---|---|
Characterization of the mouse Dazap1 gene encoding an RNA-binding protein that interacts with infertility factors DAZ and DAZL. | 2001 |
|
Deletion of the alpha-synuclein locus in a subpopulation of C57BL/6J inbred mice. | 2001 |
|
Cell adhesion and signaling on the fibronectin 1st type III repeat; requisite roles for cell surface proteoglycans and integrins. | 2001 |
|
Bone morphogenetic protein-5 (BMP-5) promotes dendritic growth in cultured sympathetic neurons. | 2001 |
|
The antioxidant activity of BHT and new phenolic compounds PYA and PPA measured by chemiluminescence. | 2001 |
|
MP20, the second most abundant lens membrane protein and member of the tetraspanin superfamily, joins the list of ligands of galectin-3. | 2001 |
|
Gastroenteritis outbreaks associated with Norwalk-like viruses and their investigation by nested RT-PCR. | 2001 |
|
Early events in the polymerization of fibrin. | 2001 |
|
Site-specific mutations of FtsZ--effects on GTPase and in vitro assembly. | 2001 |
|
Serine/threonine protein phosphatase 5 (PP5) participates in the regulation of glucocorticoid receptor nucleocytoplasmic shuttling. | 2001 |
|
Osmotic stress-dependent serine phosphorylation of the histidine kinase homologue DokA. | 2001 |
|
Capillary electrochromatographic evaluation of vitamin E-active oil constituents: tocopherols and tocotrienols. | 2001 Apr 13 |
|
Chiral separations of 1,3,4-thia- and 1,3,4-selenadiazine derivatives by use of non-aqueous capillary electrophoresis. | 2001 Apr 24 |
|
Thermolysis of free-radical initiators: tert-butylazocumene and its 1,3- and 1,4-bisazo and 1,3,5-trisazo analogues. | 2001 Apr 25 |
|
Evidence for specific ceramidase present in the intestinal contents of rats and humans. | 2001 Aug |
|
Formaldehyde production by Tris buffer in peptide formulations at elevated temperature. | 2001 Aug |
|
Comparison of ketorolac tromethamine 0.5% and rimexolone 1% to control inflammation after cataract extraction. Prospective randomized double-masked study. | 2001 Aug |
|
Analysis of vancomycin and related impurities by micellar electrokinetic capillary chromatography. Method development and validation. | 2001 Aug |
|
Mg2+-linked oligomerization modulates the catalytic activity of the Lon (La) protease from Mycobacterium smegmatis. | 2001 Aug 7 |
|
Sintering temperature effects on the in vitro bioactive response of tape cast and sintered bioactive glass-ceramic in Tris buffer. | 2001 Dec 15 |
|
Studies on digestive proteases from midgut glands of a shrimp, Penaeus indicus, and a lobster, Nephrops norvegicus: Part 1. Proteolytic activity. | 2001 Feb |
|
Analysis of glutathione by capillary electrophoresis based on sample stacking. | 2001 Jul |
|
Application of capillary electrophoresis for organic acid analysis in herbal studies. | 2001 Jul |
|
Separation of stilbenes by capillary electrophoresis and high-performance liquid chromatography. | 2001 Jul |
|
Electrophoretic migration behavior of DNA fragments in polymer solution. | 2001 Jul |
|
Recognition and strand displacement of DNA oligonucleotides by peptide nucleic acids (PNAs). High-performance ion-exchange chromatographic analysis. | 2001 Jul 13 |
|
Thiols prevent H2O2-mediated loss of sperm motility in cryopreserved bull semen. | 2001 Jul 15 |
|
Topical ketorolac tromethamine in the reduction of adverse effects of laser in situ keratomileusist. | 2001 Jun |
|
Feasibility of urinary trans, trans-muconic acid determination using high performance liquid chromatography for biological monitoring of benzene exposure. | 2001 Jun |
|
Thin-layer chromatographic behavior of rare earths on silica gel with aqueous alkaline earth metal nitrate solutions as mobile phases. | 2001 Jun |
|
Recognition of 16S rRNA by ribosomal protein S4 from Bacillus stearothermophilus. | 2001 Jun 19 |
|
Short-chain fatty acids enhance diffusional ca transport in the epithelium of the rat cecum and colon. | 2001 Jun 22 |
|
Agonist-stimulated [35S]GTPgammaS autoradiography: optimization for high sensitivity. | 2001 Jun 22 |
|
Inhibition of human CYP1A2 activity in vitro by methylxanthines: potent competitive inhibition by 8-phenyltheophylline. | 2001 Mar |
|
Ca(2+)-induced changes of surfactin conformation: a FTIR and circular dichroism study. | 2001 Mar 23 |
|
Contact allergy to trometamol. | 2001 May |
|
Therapy of malignant intracranial hypertension by controlled lumbar cerebrospinal fluid drainage. | 2001 May |
|
Considerations necessary in gathering occurrence data for selected unstable compounds in the USEPA Unregulated Contaminant Candidate List in USEPA Method 526. | 2001 May 1 |
|
Semipreparative capillary electrochromatography. | 2001 May 1 |
|
Antiplasmodial activity and cytotoxicity of bis-, tris-, and tetraquinolines with linear or cyclic amino linkers. | 2001 May 24 |
|
Maltodextrin-anionic surfactant interactions: isothermal titration calorimetry and surface tension study. | 2001 Oct |
|
Characterization of a 5'-aldehyde terminus resulting from the oxidative attack at C5' of a 2-deoxyribose on DNA. | 2001 Oct |
|
A prospective randomised trial to compare the efficacy and safety of hemabate and syntometrine for the prevention of primary postpartum haemorrhage. | 2001 Oct |
|
Use of base in the treatment of severe acidemic states. | 2001 Oct |
|
Electrophysiological and biochemical changes in rabbit hearts stored at 4 degrees C for 6 or 24 h. | 2001 Oct |
|
Generation of live rat offspring by intrauterine insemination with epididymal spermatozoa cryopreserved at -196 degrees C. | 2001 Sep |
|
Detergent-like action of the antibiotic peptide surfactin on lipid membranes. | 2001 Sep |
|
Preservation of metabolic reserves and function after storage of myocytes in hypothermic UW solution. | 2001 Sep |
|
Phosphate ion channels in sarcoplasmic reticulum of rabbit skeletal muscle. | 2001 Sep 15 |
|
Design, formation and properties of tetrahedral M(4)L(4) and M(4)L(6) supramolecular clusters. | 2001 Sep 19 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/dosage/tromethamine.html
Usual Adult Dose for Metabolic Acidosis
Associated with Cardiac Bypass Surgery:
Initial dose: 500 mL (150 mEq) by slow intravenous infusion is considered adequate for most adults; up to 1000 mL may be required in severe cases
Maximum dose: 500 mg/kg (227 mg/lb) over a period of not less than one hour
Associated with Cardiac Arrest:
If the chest is open: 2 to 6 g (62 to 185 mL of a 0.3 M solution) injected into the ventricular cavity
If the chest is not open: 3.6 to 10.8 g (111 to 333 mL of a 0.3 M solution) injected into a larger peripheral vein if the chest is not open
Comment: Do not inject into the cardiac muscle
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/18248745
25-100 mM Tris (Tromethamine) completely inhibits starch-synthase
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:34:22 GMT 2025
by
admin
on
Mon Mar 31 17:34:22 GMT 2025
|
Record UNII |
023C2WHX2V
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C802
Created by
admin on Mon Mar 31 17:34:22 GMT 2025 , Edited by admin on Mon Mar 31 17:34:22 GMT 2025
|
||
|
WHO-VATC |
QB05XX02
Created by
admin on Mon Mar 31 17:34:22 GMT 2025 , Edited by admin on Mon Mar 31 17:34:22 GMT 2025
|
||
|
EPA PESTICIDE CODE |
83901
Created by
admin on Mon Mar 31 17:34:22 GMT 2025 , Edited by admin on Mon Mar 31 17:34:22 GMT 2025
|
||
|
WHO-VATC |
QB05BB03
Created by
admin on Mon Mar 31 17:34:22 GMT 2025 , Edited by admin on Mon Mar 31 17:34:22 GMT 2025
|
||
|
WHO-ATC |
B05XX02
Created by
admin on Mon Mar 31 17:34:22 GMT 2025 , Edited by admin on Mon Mar 31 17:34:22 GMT 2025
|
||
|
WHO-ATC |
B05BB03
Created by
admin on Mon Mar 31 17:34:22 GMT 2025 , Edited by admin on Mon Mar 31 17:34:22 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
023C2WHX2V
Created by
admin on Mon Mar 31 17:34:22 GMT 2025 , Edited by admin on Mon Mar 31 17:34:22 GMT 2025
|
PRIMARY | |||
|
m11221
Created by
admin on Mon Mar 31 17:34:22 GMT 2025 , Edited by admin on Mon Mar 31 17:34:22 GMT 2025
|
PRIMARY | Merck Index | ||
|
7328
Created by
admin on Mon Mar 31 17:34:22 GMT 2025 , Edited by admin on Mon Mar 31 17:34:22 GMT 2025
|
PRIMARY | |||
|
D014325
Created by
admin on Mon Mar 31 17:34:22 GMT 2025 , Edited by admin on Mon Mar 31 17:34:22 GMT 2025
|
PRIMARY | |||
|
DTXSID2023723
Created by
admin on Mon Mar 31 17:34:22 GMT 2025 , Edited by admin on Mon Mar 31 17:34:22 GMT 2025
|
PRIMARY | |||
|
2771
Created by
admin on Mon Mar 31 17:34:22 GMT 2025 , Edited by admin on Mon Mar 31 17:34:22 GMT 2025
|
PRIMARY | |||
|
023C2WHX2V
Created by
admin on Mon Mar 31 17:34:22 GMT 2025 , Edited by admin on Mon Mar 31 17:34:22 GMT 2025
|
PRIMARY | |||
|
C47775
Created by
admin on Mon Mar 31 17:34:22 GMT 2025 , Edited by admin on Mon Mar 31 17:34:22 GMT 2025
|
PRIMARY | |||
|
10865
Created by
admin on Mon Mar 31 17:34:22 GMT 2025 , Edited by admin on Mon Mar 31 17:34:22 GMT 2025
|
PRIMARY | RxNorm | ||
|
201-064-4
Created by
admin on Mon Mar 31 17:34:22 GMT 2025 , Edited by admin on Mon Mar 31 17:34:22 GMT 2025
|
PRIMARY | |||
|
100000092541
Created by
admin on Mon Mar 31 17:34:22 GMT 2025 , Edited by admin on Mon Mar 31 17:34:22 GMT 2025
|
PRIMARY | |||
|
6365
Created by
admin on Mon Mar 31 17:34:22 GMT 2025 , Edited by admin on Mon Mar 31 17:34:22 GMT 2025
|
PRIMARY | |||
|
TRIS
Created by
admin on Mon Mar 31 17:34:22 GMT 2025 , Edited by admin on Mon Mar 31 17:34:22 GMT 2025
|
PRIMARY | |||
|
9754
Created by
admin on Mon Mar 31 17:34:22 GMT 2025 , Edited by admin on Mon Mar 31 17:34:22 GMT 2025
|
PRIMARY | |||
|
SUB11336MIG
Created by
admin on Mon Mar 31 17:34:22 GMT 2025 , Edited by admin on Mon Mar 31 17:34:22 GMT 2025
|
PRIMARY | |||
|
3408
Created by
admin on Mon Mar 31 17:34:22 GMT 2025 , Edited by admin on Mon Mar 31 17:34:22 GMT 2025
|
PRIMARY | |||
|
6503
Created by
admin on Mon Mar 31 17:34:22 GMT 2025 , Edited by admin on Mon Mar 31 17:34:22 GMT 2025
|
PRIMARY | |||
|
1698002
Created by
admin on Mon Mar 31 17:34:22 GMT 2025 , Edited by admin on Mon Mar 31 17:34:22 GMT 2025
|
PRIMARY | |||
|
77-86-1
Created by
admin on Mon Mar 31 17:34:22 GMT 2025 , Edited by admin on Mon Mar 31 17:34:22 GMT 2025
|
PRIMARY | |||
|
1108
Created by
admin on Mon Mar 31 17:34:22 GMT 2025 , Edited by admin on Mon Mar 31 17:34:22 GMT 2025
|
PRIMARY | |||
|
DB03754
Created by
admin on Mon Mar 31 17:34:22 GMT 2025 , Edited by admin on Mon Mar 31 17:34:22 GMT 2025
|
PRIMARY | |||
|
CHEMBL1200391
Created by
admin on Mon Mar 31 17:34:22 GMT 2025 , Edited by admin on Mon Mar 31 17:34:22 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|